Quantcast

Latest Avastin Stories

2009-03-09 07:00:00

A Drug That Improves Survival, When Added to Temodar/Temodal, Would Earn a 65 Percent Patient Share in the U.S. and a 30 Percent Patient Share in Europe in Newly Diagnosed Glioblastoma Multiforme, According to a New Report from Decision Resources WALTHAM, Mass., March 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed oncologists identify a therapy's effect on overall survival as the...

2009-01-26 07:00:00

New data demonstrates that Angiolix has similar efficacy to Avastin alone and in combination with other chemotherapeutics, with potentially less side-effects; study validates results seen in Previous Breast Cancer Model DALLAS, Jan. 26 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) presented new data this week on its proprietary humanized monoclonal antibody, Angiolix, which confirmed that Angiolix(R) binds with high affinity to the its target, lactadherin,...

2008-12-08 07:00:00

Generic Erosion Will Reduce Sales of Schering-Plough's Temodar/Temodal, the Current Market Leader, According to a New Report from Decision Resources WALTHAM, Mass., Dec. 8 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the approval of agents to treat glioma, most notably Roche/Genentech/Chugai's Avastin, will drive market sales to more than double to more than $1.8 billion in 2017 in the United...

2008-11-19 12:18:21

A drug touted as a safer, gentler way to treat cancer increases the risk of blood clots, a U.S. study in the Journal of the American Medical Association said. A study showed about 12 percent of the people taking Avastin developed blood clots in the veins, which is a rate that's 30 percent higher than among patients not taking the drug, USA Today reported. Because clots are among the leading causes of sickness and death among cancer patients, the study's authors recommended Avastin get the...

2008-11-04 09:00:30

Genentech, a biotechnology company, has submitted a supplemental biologics license application to the FDA for Avastin as a therapy for people with previously treated glioblastoma. If accepted by the FDA, the application would be considered for an accelerated approval that allows provisional approval of medicines for cancer or other life-threatening diseases based on preliminary evidence suggesting clinical benefit. The Avastin supplemental biologics license application (sBLA) is based on...

2008-11-03 09:00:06

Genentech, Inc. (NYSE:DNA) today announced that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Avastin(R) (bevacizumab) as a therapy for people with previously treated glioblastoma. If accepted by the FDA, the application would be considered for an accelerated approval that allows provisional approval of medicines for cancer or other life-threatening diseases based on preliminary evidence suggesting clinical...

2008-10-20 12:00:31

Genentech, a biotechnology company, has announced that it has been informed by the National Surgical Adjuvant Breast and Bowel Project that an ongoing Phase III study of Avastin plus chemotherapy in patients with early-stage colon cancer will continue as planned. The National Surgical Adjuvant Breast and Bowel Project's (NSABP) decision to continue the trial was based on a recommendation from an independent data monitoring committee (DMC) after a planned interim analysis. The study of...

2008-10-20 03:00:08

Genentech, Inc. (NYSE:DNA) today announced that it has been informed by the National Surgical Adjuvant Breast and Bowel Project (NSABP) that an ongoing Phase III study (NSABP C-08) of Avastin(R) (bevacizumab) plus chemotherapy in patients with early-stage colon cancer will continue as planned. The NSABP's decision to continue the trial was based on a recommendation from an independent Data Monitoring Committee (DMC) after a planned interim analysis. The study of 2,710 patients is being...

2008-10-14 09:00:45

WALTHAM, Mass., Oct. 14 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, of the many targeted cancer agents in Phase III clinical trials in the adjuvant setting, surveyed oncologists say that Genentech/Roche/Chugai's Avastin in early-stage colorectal cancer holds the most promise to achieve regulatory approval. Additionally, more than half of surveyed oncologists indicated that the minimum benefit...

2008-10-06 21:00:15

By ; wire Shares of South San Francisco-based Genentech dropped nearly 8 percent after the company announced with OSI Pharmaceuticals that a combination of two cancer drugs, Avastin with Tarceva, missed its primary goal in a clinical trial, failing to improve survival for patients with late-stage lung cancer. The trial focused on patients who had not responded to chemotherapy. But patients who were treated with Avastin and Tarceva did not survive significantly longer than those who were...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related